{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:50:49Z","timestamp":1753876249073,"version":"3.41.2"},"reference-count":32,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["1159"],"award-info":[{"award-number":["1159"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The coronavirus disease (COVID-19) pandemic has imposed deployment of an effective vaccine as a worldwide health priority. The new variants of SARS-CoV-2 have also brought serious concerns due to virus eradiation hesitancy. In this study, we evaluated the protective immune system activity of a recombinant viral vector-based vaccine candidate encoding a fusion spike, membrane and nucleocapsid proteins, Spike (528\u20131273aa)-M-N, in BALB\/c via two different routes of delivery, intranasal and subcutaneous. The immune responses were then assessed through specific SARS-CoV-2 antibodies, interleukin and granzyme B secretion. The outcomes showed that the IgG titer and IgA secretion was higher in intranasal route in comparison with the subcutaneous, and what is more, a higher titer of IL-4 was detected through the intranasal route, whereas IFN-\u03b3 was highly induced via the subcutaneous route. The cytotoxic cell activities were mostly achieved via subcutaneous route immunization. Vaccination with the target antigen is immunogenic and led to induction of specific antibodies. Both humoral and cellular immunity arms were well activated in immunized mice, especially through intranasal route with detectable IgA and IgG. Therefore, implication of the platform as a potential vaccine candidate has potential as a future prophylactic vaccine that guarantees further investigations for the assessment of its immunogenicity in humans.<\/jats:p>","DOI":"10.1093\/femspd\/ftad021","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:42:05Z","timestamp":1693892525000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity evaluation of a novel virus-like particle vaccine candidate against SARS-CoV-2 in BALB\/c"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1762-4907","authenticated-orcid":false,"given":"Golnaz","family":"Bahramali","sequence":"first","affiliation":[{"name":"Department of Hepatitis and AIDS and Blood borne diseases, Pasteur Institute of Iran , Tehran 1316946551 , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6639-7221","authenticated-orcid":false,"given":"Maryam","family":"Mashhadi\u00a0Abolghasem\u00a0Shirazi","sequence":"additional","affiliation":[{"name":"Molecular Virology Department, Pasteur Institute of Iran , Tehran 1316946551 , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5721-1376","authenticated-orcid":false,"given":"Mina","family":"Hannan","sequence":"additional","affiliation":[{"name":"Department of Hepatitis and AIDS and Blood borne diseases, Pasteur Institute of Iran , Tehran 1316946551 , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2186-0774","authenticated-orcid":false,"given":"Mohammad Reza","family":"Aghasadeghi","sequence":"additional","affiliation":[{"name":"Department of Hepatitis and AIDS and Blood borne diseases, Pasteur Institute of Iran , Tehran 1316946551 , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-2488","authenticated-orcid":false,"given":"Mohammad Sadeq","family":"Khosravy","sequence":"additional","affiliation":[{"name":"Department of Rabies Research (B), WHO Collaborating Center for Reference and Research on Rabies, Tehran 1316946551, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Arjmand","sequence":"additional","affiliation":[{"name":"Department of Hepatitis and AIDS and Blood borne diseases, Pasteur Institute of Iran , Tehran 1316946551 , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-179X","authenticated-orcid":false,"given":"Seyed Mehdi","family":"Sadat","sequence":"additional","affiliation":[{"name":"Department of Hepatitis and AIDS and Blood borne diseases, Pasteur Institute of Iran , Tehran 1316946551 , Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"2023092722234980100_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/jocn.15951","article-title":"COVID-19 vaccination intention in the first year of the pandemic: a systematic review","volume":"31","author":"Al-Amer","year":"2022","journal-title":"J Clin Nurs"},{"key":"2023092722234980100_bib2","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.abe1502","article-title":"Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate","volume":"370","author":"Bangaru","year":"2020","journal-title":"Science"},{"key":"2023092722234980100_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/eji.200636959","article-title":"Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design","volume":"38","author":"Bessa","year":"2008","journal-title":"Eur J Immunol"},{"key":"2023092722234980100_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/jphp.12353","article-title":"Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?","volume":"67","author":"Bill","year":"2015","journal-title":"J Pharm Pharmacol"},{"key":"2023092722234980100_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10060944","article-title":"Influenza virus-like particle-based hybrid vaccine containing RBD induces immunity against Influenza and SARS-CoV-2 viruses","volume":"10","author":"Bommireddy","year":"2022","journal-title":"Vaccines"},{"key":"2023092722234980100_bib6","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2213-2600(21)00559-2","article-title":"Omicron variant and booster COVID-19 vaccines","volume":"10","author":"Burki","year":"2022","journal-title":"The Lancet Respiratory Medicine"},{"key":"2023092722234980100_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac109","article-title":"Duration of immune protection of SARS-CoV-2 natural infection against reinfection","volume":"29","author":"Chemaitelly","year":"2022","journal-title":"J Travel Med"},{"key":"2023092722234980100_bib8","first-page":"8","article-title":"SARS-CoV-2 targets and COVID-19 vaccines","volume":"16","author":"Currier","year":"2021","journal-title":"COVID"},{"key":"2023092722234980100_bib9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tibtech.2008.08.002","article-title":"Structure-based antigen design: a strategy for next generation vaccines","volume":"26","author":"Dormitzer","year":"2008","journal-title":"Trends Biotechnol"},{"key":"2023092722234980100_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00005-009-0040-y","article-title":"Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens","volume":"57","author":"Gosselin","year":"2009","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"2023092722234980100_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal ChAd vaccine protects upper and lower Respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"2023092722234980100_bib12","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/jcm9041225","article-title":"The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control","volume":"9","author":"Helmy","year":"2020","journal-title":"J Clin Med"},{"key":"2023092722234980100_bib13","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1600-0854.2011.01281.x","article-title":"Dynamic imaging of cell-free and cell-associated viral capture in mature dendritic cells","volume":"12","author":"Izquierdo-Useros","year":"2011","journal-title":"Traffic"},{"key":"2023092722234980100_bib15","doi-asserted-by":"crossref","first-page":"e24426","DOI":"10.1002\/jcla.24426","article-title":"Clinical symptoms, diagnosis, treatment, and outcome of COVID-19-associated encephalitis: a systematic review of case reports and case series","volume":"36","author":"Koupaei","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"2023092722234980100_bib16","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"2023092722234980100_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/1567201817666200317121728","article-title":"Production of recombinant HIV-1 p24-nef protein in two forms as potential candidate vaccines in three vehicles","volume":"17","author":"Larijani","year":"2020","journal-title":"Curr Drug Delivery"},{"key":"2023092722234980100_bib18","doi-asserted-by":"crossref","first-page":"198403","DOI":"10.1016\/j.virusres.2021.198403","article-title":"Evaluation of transduced dendritic cells expressing HIV-1 p24-nef antigens in HIV-specific cytotoxic T cells induction as a therapeutic candidate vaccine","volume":"298","author":"Larijani","year":"2021","journal-title":"Virus Res"},{"key":"2023092722234980100_bib19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2174\/1570162X17666190102151717","article-title":"In silico design and immunologic evaluation of HIV-1 p24-nef fusion protein to approach a therapeutic vaccine candidate","volume":"16","author":"Larijani","year":"2018","journal-title":"Curr HIV Res"},{"key":"2023092722234980100_bib20","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"4","author":"Mohsen","year":"2017","journal-title":"Semin Immunol"},{"key":"2023092722234980100_bib21","article-title":"Intranasal administration of a VLP-based vaccine induces neutralizing antibodies against SARS-CoV-2 and variants of concern","volume":"7","author":"Rothen","year":"2022","journal-title":"Allergy"},{"key":"2023092722234980100_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.611337","article-title":"Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection","volume":"11","author":"Russell","year":"2020","journal-title":"Front Immunol"},{"key":"2023092722234980100_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12033-021-00303-0","article-title":"Bioinformatics analysis of SARS-CoV-2 to approach an effective vaccine candidate against COVID-19","volume":"63","author":"Sadat","year":"2021","journal-title":"Mol Biotechnol"},{"key":"2023092722234980100_bib24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/157016211795945223","article-title":"Application of SCR priming VLP boosting as a novel vaccination strategy against HIV-1","volume":"9","author":"Sadat","year":"2011","journal-title":"Curr HIV Res"},{"key":"2023092722234980100_bib25","doi-asserted-by":"crossref","first-page":"105296","DOI":"10.1016\/j.micpath.2021.105296","article-title":"SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up","volume":"161","author":"Salehi-Vaziri","year":"2021","journal-title":"Microb Pathog"},{"key":"2023092722234980100_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbrc.2021.01.073","article-title":"The nucleocapsid protein triggers the main humoral immune response in COVID-19 patients","volume":"543","author":"Smits","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"2023092722234980100_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2022","journal-title":"Front Microbiol"},{"key":"2023092722234980100_bib28","first-page":"434","article-title":"Construction and production of HIV-VLP harboring MPER-V3 for potential vaccine study","volume":"15","author":"Tohidi","year":"2017","journal-title":"Curr HIV Res"},{"key":"2023092722234980100_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"2023092722234980100_bib30","doi-asserted-by":"crossref","first-page":"587269","DOI":"10.3389\/fcimb.2020.587269","article-title":"SARS-CoV-2: structure, biology, and structure-based therapeutics development","volume":"10","author":"Wang","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"2023092722234980100_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s43856-022-00177-6","article-title":"Mapping global acceptance and uptake of COVID-19 vaccination: a systematic review and meta-analysis","volume":"2","author":"Wang","year":"2022","journal-title":"Commun Med"},{"key":"2023092722234980100_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10930-020-09901-4","article-title":"The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19","volume":"39","author":"Yoshimoto","year":"2020","journal-title":"Protein J"},{"key":"2023092722234980100_bib33","doi-asserted-by":"crossref","first-page":"103762","DOI":"10.1016\/j.ebiom.2021.103762","article-title":"Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models","volume":"75","author":"Zhou","year":"2022","journal-title":"EBioMedicine"}],"container-title":["Pathogens and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/femspd\/advance-article-pdf\/doi\/10.1093\/femspd\/ftad021\/51355346\/ftad021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/femspd\/article-pdf\/doi\/10.1093\/femspd\/ftad021\/51775384\/ftad021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/femspd\/article-pdf\/doi\/10.1093\/femspd\/ftad021\/51775384\/ftad021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T22:24:26Z","timestamp":1695853466000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/femspd\/article\/doi\/10.1093\/femspd\/ftad021\/7259893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1093\/femspd\/ftad021","relation":{},"ISSN":["2049-632X"],"issn-type":[{"type":"electronic","value":"2049-632X"}],"subject":[],"published-other":{"date-parts":[[2023]]},"published":{"date-parts":[[2023]]},"article-number":"ftad021"}}